RxDoctor Payments Data

John Nelson, MD

Pain Medicine · Oklahoma City, OKNPI 1174551923

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $19,833 of the $25,618 with a category attached, or 77.4%. Epimed International, Inc accounts for 77.4% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2021 at $5,476 and has fallen 95.3% since, to $259 in 2025. Among pain medicine clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,618in general payments, 2019–2025

Across 176 payments — averaging $145.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Epimed International, Inc$20K
  • Medtronic$776
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$624
  • Spinal Simplicity, LLC$589
  • Abbott$380
  • Genesys Orthopedics Systems, L.L.C.$349
  • plus $3K from 25 others

What the payments were for

  • Royalty or licence$19,83377%
  • Travel & lodging$5892%
  • Food & beverage$5,19520%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,618 in reported general payments places this provider in the 90th percentile of 68 pain medicine providers in Oklahoma.

See all pain medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$28,783
Medicare patients
64
Services billed
234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen804$186,658
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen2,532$93,015
ProlateOxycodone Hcl/Acetaminophen12$47,733
BelbucaBuprenorphine Hcl21$16,821
OxycontinOxycodone Hcl33$12,664
Oxycodone Hcl705$11,889
Morphine Sulfate ErMorphine Sulfate159$4,254
Morphine Sulfate123$3,065
Fentanyl38$2,305
Pregabalin122$2,024
Buprenorphine13$1,989
Lidocaine19$1,982
Tramadol Hcl105$1,592
Gabapentin107$1,318
Naloxone Hcl17$1,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Forte Bio-pharma LLCProlate$295$47,73312 claims
Collegium Pharmaceutical, Inc.Belbuca$331$16,82121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 68 pain medicine providers in Oklahoma.

Other pain medicine in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →